Overview

  • Product name
    TAK 715
  • Description
    Potent p38 MAPK inhibitor
  • Biological description
    Potent p38 MAPK inhibitor (IC50 = 7.1 nM at p38 MAPKα). Additionally inhibits Wnt-3a stimulated β-catenin signaling and shows cross-reactivity with casein kinase Iδ and ε. Antirheumatic. Active in vivo.
  • Purity
    > 99%

Properties

References

This product has been referenced in:
  • Verkaar F  et al. Inhibition of Wnt/ß-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Id/?. Chem Biol 18:485-94 (2011). Read more (PubMed: 21513885) »
  • Roberts PJ & Der CJ Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-310 (2007). Read more (PubMed: 17496923) »
  • Miwatashi S  et al. Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem 48:5966-79 (2005). Read more (PubMed: 16162000) »

See 0 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab120989.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

Sign up